Inhibition of the catalytic function of activation-induced cytidine deaminase promotes apoptosis of germinal center B cells in BXD2 mice
Open Access
- 21 January 2011
- journal article
- systemic lupus-erythematosus
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (7) , 2038-2048
- https://doi.org/10.1002/art.30257
Abstract
Objective To determine whether functional suppression of the catalytic domain of activation‐induced cytidine deaminase (AID) can suppress the hyperreactive germinal center (GC) responses in BXD2 mice. Methods We generated transgenic BXD2 mice expressing a dominant‐negative (DN) form of Aicda at the somatic hypermutation site (BXD2‐Aicda‐DN–transgenic mice). Real‐time quantitative reverse transcriptase–polymerase chain reaction was used to determine the expression of Aicda and DNA damage/repair genes. Enzyme‐linked immunosorbent assay was used to measure serum levels of autoantibodies and immune complexes (ICs). Development of GCs and antibody‐containing ICs as well as numbers of proliferative and apoptotic cells were determined using flow cytometry and/or immunohistochemical analyses. Development of arthritis and kidney disease was evaluated histologically in 6–8‐month‐old mice. Results Suppression of the somatic hypermutation function of AID resulted in a significant decrease in autoantibody production without affecting the expression of DNA damage–related genes in GC B cells of BXD2‐Aicda‐DN–transgenic mice. There was decreased proliferation, increased apoptosis, increased expression of caspase 9 messenger RNA in GC B cells, and lower numbers of GCs in the spleens of BXD2‐Aicda‐DN–transgenic mice. Decreased GC response was associated with lower levels of IgG‐containing ICs. Anti‐IgM– and anti‐CD40 plus anti‐Ig–induced B cell proliferative responses were decreased in BXD2‐Aicda‐DN–transgenic mice. Conclusion Inhibition of the AID somatic hypermutation function in BXD2 mice suppressed development of spontaneous GCs, generation of autoantibody‐producing B cells, and autoimmunity in BXD2 mice. Suppression of AID catalytic function to limit selection‐based survival of GC B cells could become a novel therapy for the treatment of autoimmune disease.Keywords
This publication has 51 references indexed in Scilit:
- IL-17 Activates the Canonical NF-κB Signaling Pathway in Autoimmune B Cells of BXD2 Mice To Upregulate the Expression of Regulators of G-Protein Signaling 16The Journal of Immunology, 2010
- Marginal Zone Precursor B Cells as Cellular Agents for Type I IFN–Promoted Antigen Transport in AutoimmunityThe Journal of Immunology, 2009
- Increased Expression of Activation‐Induced Cytidine Deaminase is Associated with Anti‐CCP and Rheumatoid Factor in Rheumatoid ArthritisScandinavian Journal of Immunology, 2009
- AID constrains germinal center size by rendering B cells susceptible to apoptosisBlood, 2009
- Ectopic Lymphoid Structures Support Ongoing Production of Class-Switched Autoantibodies in Rheumatoid SynoviumPLoS Medicine, 2009
- Activation‐induced deaminase heterozygous MRL/lpr mice are delayed in the production of high‐affinity pathogenic antibodies and in the development of lupus nephritisImmunology, 2008
- Activation-Induced Cytidine Deaminase Deficiency Causes Organ-Specific Autoimmune DiseasePLOS ONE, 2008
- Peripheral B cell subsetsPublished by Elsevier ,2008
- Blockade of lymphotoxin pathway exacerbates autoimmune arthritis by enhancing the Th1 responseArthritis & Rheumatism, 2005
- Hyper-IgM syndrome with putative dominant negative mutation in activation-induced cytidine deaminaseJournal of Allergy and Clinical Immunology, 2003